Skip to content

Medicinal mushroom compound × gout chokepoint mapping

Fungal natural products may expose gout weaknesses across urate production, renal or intestinal transport, inflammasome signaling, and adjacent inflammatory pathways. COMP-014 attempted a broad compound-to-target map, but the artifact cannot support that map.

Verdict

COMP-014 is invalidated for scientific, quantitative, and decision use. No compound row, count, target mapping, rank, safety flag, production claim, or advancement decision survives as current evidence.

The retired search mixed query-hint species labels with provenance, treated a permissive inclusion flag as if it were a toxicity screen, used an unstable compound-deduplication boundary, and ranked heterogeneous endpoints and polarities together. Historical Phase 7 outputs also embedded purchase, cultivation, cost, and practical-SOP guidance that the search could not validate.

The live tree retains only the non-runnable tombstone and its hash-bound invalidation record. Git preserves the retired files.

Research rebuild

The failure does not reject fungal chemistry. Exact-material reproducibility, ADA, PINK1 or mitophagy, urate transport, urate production, inflammasome, redox, barrier, and direct C5aR1-screen ideas remain eligible research questions only where their owning pages establish them independently from primary sources.

A replacement screen must treat query labels as retrieval hints rather than provenance, distinguish retained-for-review from safe, preserve assay endpoint and effect polarity, use a declared identity/deduplication rule, and treat bounded non-retrieval as a search result rather than biological absence.

Evidence needed for any named lead

Before a compound, extract, or species can be prioritized, preserve:

  • exact chemical or material identity;
  • source species and whether the compound is synthesized, accumulated from substrate, or merely query-associated;
  • primary source and verified location;
  • target, substrate, assay system, effect polarity, and evidence level;
  • direct function rather than binding or expression alone;
  • free parent and metabolite exposure in the relevant compartment;
  • off-target, toxicity, barrier-integrity, and viability data;
  • reproducible production or extraction yield only after the biological gate passes.

For ABCG2, a drug-substrate interaction or expression change is not an intestinal urate-flux result. For a formula or whole extract, the whole-material phenotype does not establish which component caused it.

Sourcing and delivery

Delivery is lead-specific:

  • a defined small molecule may favor synthesis, purification, or formulation;
  • a native fungal metabolite may favor controlled cultivation and extraction;
  • a polysaccharide or whole extract requires composition and batch-release assays;
  • heterologous expression becomes relevant only when it solves a demonstrated yield, stability, or localization constraint.

The fact that a lead is fungal-associated does not make a mushroom, koji, or engineered chassis the default route.

Discriminating workflow

  1. Rehydrate a lead from the primary source and verify material, source attribution, polarity, assay, and evidence level.
  2. Measure or justify free exposure in the compartment where the mechanism is proposed.
  3. Run the mechanism-matched functional assay with attribution and safety controls.
  4. Compare sourcing and delivery routes only for leads that survive the biological gate.
  5. Treat a negative result as local to the tested material, exposure, endpoint, and route.

Tombstone

Nothing from COMP-014 may nominate or prioritize a compound without fresh primary-source rehydration.